Canagliflozin Not Linked to Fractures in Large Database Study Canagliflozin Not Linked to Fractures in Large Database Study
Risk associated with SGLT2 inhibitor may be limited to patients with type 2 diabetes who have additional fracture risk.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - December 31, 2018 Category: Consumer Health News Tags: Diabetes & Endocrinology News Source Type: news
Is One SGLT2 (Or GLP-1) Just Like Another for Cardiac Benefit? Is One SGLT2 (Or GLP-1) Just Like Another for Cardiac Benefit?
A new consensus document from ACC acknowledges the ' twofer ' benefits of some antidiabetic drugs.Medscape Internal Medicine (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - December 31, 2018 Category: Consumer Health News Tags: Family Medicine/Primary Care Commentary Source Type: news
SGLT2 Inhibitors: Is This the Start of a New Era? SGLT2 Inhibitors: Is This the Start of a New Era?
Gregory Nichols discusses exciting new clinical trial results demonstrating the benefits of SGLT2 inhibitors, as presented at the AHA 2018 Scientific Sessions.Medscape Diabetes & Endocrinology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - December 7, 2018 Category: Consumer Health News Tags: Diabetes & Endocrinology Article Source Type: news
Certain SGLT2 Inhibitors, GLP-1 RAs for T2DM Also Cut CV Risk
THURSDAY, Nov. 29, 2018 -- Certain sodium-glucose cotransporter 2 (SGLT2) inhibitors and glucagon-like peptide 1 receptor agonists (GLP-1 RAs) demonstrate significant cardiovascular (CV) benefit and should be used for reducing CV risk in patients... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - November 29, 2018 Category: Pharmaceuticals Source Type: news
Pumps, Pipes, and Filters: SGLT2 Inhibitors for Most Type 2 Diabetes? Pumps, Pipes, and Filters: SGLT2 Inhibitors for Most Type 2 Diabetes?
The new SGLT2 inhibitors should be considered for use in most patients with type 2 diabetes because of their benefits in reducing heart failure and renal disease, according to a new meta-analysis.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - November 23, 2018 Category: Consumer Health News Tags: Diabetes & Endocrinology News Source Type: news
